The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): A retrospective study.
 
Emily Lemke
No Relationships to Disclose
 
Amishi Yogesh Shah
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Pavlos Msaouel
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Exelixis
 
Eric Jonasch
Consulting or Advisory Role - Cerulean Pharma; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Onyx; Pfizer
Travel, Accommodations, Expenses - Cerulean Pharma; Novartis; Pfizer
 
Aradhana M. Venkatesan
No Relationships to Disclose
 
Anuradha Chandramohan
No Relationships to Disclose
 
Cihan Duran
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Matthew T. Campbell
Consulting or Advisory Role - AstraZeneca; Eisai; EMD Serono; Pfizer